Bernstein Sticks to Their Hold Rating for BeiGene (ONC)
Bernstein analyst Rebecca Liang maintained a Hold rating on BeiGene (ONC – Research Report) today and set a price target of $259.00. The ...
BeiGene price target raised to $259 from $207 at Bernstein
Bernstein raised the firm’s price target on BeiGene (ONC) to $259 from $207 and keeps a Market Perform rating on the shares. The firm sees more ...
pharmaphorum4d
BeiGene's Brukinsa FDA approved for CLL/SLL
Beijing-based pharma, BeiGene’s Brukinsa (zanubrutinib) has been approved by the US Food and Drug Administration (FDA) for chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL).
Yahoo Finance7d
BeiGene, Ltd. (ONC)
After hours: March 7 at 7:54:21 PM EST Loading Chart for ONC ...